Survivin gene silencing sensitizes prostate cancer cells to selenium growth inhibition

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Liu, Xichun ^a,b   Gao, Ruijuan ^a,b   Dong, Yan ^b,c   Gao, Lifang ^a   Zhao, Yanying ^a   Zhao, Lijuan ^a   Zhao, Xuejian ^a   Zhang, Haitao ^a,b,c  

^a Basic Medical College   (China)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Louisiana Cancer Research Consortium   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; METHYLSELENINIC ACID; METHYLSELENOCYSTEINE; PROPIDIUM IODIDE; SELENIUM; SELENIUM DERIVATIVE; SHORT HAIRPIN RNA; SURVIVIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BIRC5 PROTEIN, MOUSE; CYSTEINE; DRUG DERIVATIVE; INHIBITOR OF APOPTOSIS PROTEIN; MESSENGER RNA; METHYLSELENIC ACID; ORGANOSELENIUM DERIVATIVE; REPRESSOR PROTEIN; SELENOMETHYLSELENOCYSTEINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; FLOW CYTOMETRY; GENE SILENCING; GENETIC TRANSFECTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIZATION; TUMOR GROWTH; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; ENZYME IMMUNOASSAY; GENETICS; METABOLISM; NEOPLASM; PATHOLOGY; PROGNOSIS; PROSTATE TUMOR; SURVIVAL RATE; TUMOR CELL LINE;

ANIMALS; ANTICARCINOGENIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CYSTEINE; DOWN-REGULATION; DRUG SYNERGISM; GENE SILENCING; HUMANS; IMMUNOENZYME TECHNIQUES; INHIBITOR OF APOPTOSIS PROTEINS; MALE; MICE; MICE, NUDE; NEOPLASMS, HORMONE-DEPENDENT; ORGANOSELENIUM COMPOUNDS; PROGNOSIS; PROSTATIC NEOPLASMS; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE;

EID: 77955286768     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-418     Document Type: Article

References (34)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. Cancer statistics, 2006. CA Cancer J Clin 2006, 56:106-130. 10.3322/canjclin.56.2.106, 16514137.
2. Klein EA, Kupelian PA. Localized prostate cancer: radiation or surgery?. Urol Clin North Am 2003, 30:315-30ix. 10.1016/S0094-0143(02)00179-9, 12735507.
3. Altieri DC, Marchisio PC. Survivin apoptosis: an interloper between cell death and cell proliferation in cancer. Lab Invest 1999, 79:1327-1333.
4. Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 2003, 22:8581-8589. 10.1038/sj.onc.1207113, 14634620.
5. Shariat SF, Lotan Y, Saboorian H, Khoddami SM, Roehrborn CG, Slawin KM, Ashfaq R. Survivin expression is associated with features of biologically aggressive prostate carcinoma. Cancer 2004, 100:751-757. 10.1002/cncr.20039, 14770431.
6. Brooks JD, Metter EJ, Chan DW, Sokoll LJ, Landis P, Nelson WG, Muller D, Andres R, Carter HB. Plasma selenium level before diagnosis and the risk of prostate cancer development. J Urol 2001, 166:2034-2038. 10.1016/S0022-5347(05)65500-0, 11696701.
7. Helzlsouer KJ, Huang HY, Alberg AJ, Hoffman S, Burke A, Norkus EP, Morris JS, Comstock GW. Association between alpha-tocopherol, gamma-tocopherol, selenium, and subsequent prostate cancer. J Natl Cancer Inst 2000, 92:2018-2023. 10.1093/jnci/92.24.2018, 11121464.
8. Nomura AM, Lee J, Stemmermann GN, Combs GF. Serum selenium and subsequent risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2000, 9:883-887.
9. Clark LC, Combs GF, Turnbull BW, Slate EH, Chalker DK, Chow J, Davis LS, Glover RA, Graham GF, Gross EG, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 1996, 276:1957-1963. 10.1001/jama.276.24.1957, 8971064.
10. Duffield-Lillico AJ, Dalkin BL, Reid ME, Turnbull BW, Slate EH, Jacobs ET, Marshall JR, Clark LC. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU Int 2003, 91:608-612. 10.1046/j.1464-410X.2003.04167.x, 12699469.
11. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009, 301:39-51. 10.1001/jama.2008.864, 19066370.
12. Ip C, Ganther HE. Activity of methylated forms of selenium in cancer prevention. Cancer Res 1990, 50:1206-1211.
13. Ip C, Hayes C, Budnick RM, Ganther HE. Chemical form of selenium, critical metabolites, and cancer prevention. Cancer Res 1991, 51:595-600.
14. Ip C. Lessons from basic research in selenium and cancer prevention. J Nutr 1998, 128:1845-1854.
15. Yamaguchi K, Uzzo RG, Pimkina J, Makhov P, Golovine K, Crispen P, Kolenko VM. Methylseleninic acid sensitizes prostate cancer cells to TRAIL-mediated apoptosis. Oncogene 2005, 24:5868-5877. 10.1038/sj.onc.1208742, 15897871.
16. Zu K, Ip C. Synergy between selenium and vitamin E in apoptosis induction is associated with activation of distinctive initiator caspases in human prostate cancer cells. Cancer Res 2003, 63:6988-6995.
17. Burk RF, Hill KE, Motley AK, Austin LM, Norsworthy BK. Deletion of selenoprotein P upregulates urinary selenium excretion and depresses whole-body selenium content. Biochim Biophys Acta 2006, 1760:1789-1793. 1761947, 17014962.
18. Chun JY, Hu Y, Pinder E, Wu J, Li F, Gao AC. Selenium inhibition of survivin expression by preventing Sp1 binding to its promoter. Mol Cancer Ther 2007, 6:2572-2580. 10.1158/1535-7163.MCT-07-0172, 2821810, 17876054.
19. Liu T, Brouha B, Grossman D. Rapid induction of mitochondrial events and caspase-independent apoptosis in Survivin-targeted melanoma cells. Oncogene 2004, 23:39-48. 10.1038/sj.onc.1206978, 2292403, 14712209.
20. Kaur P, Kallakury BS, Sheehan CE, Fisher HA, Kaufman RP, Ross JS. Survivin and Bcl-2 expression in prostatic adenocarcinomas. Arch Pathol Lab Med 2004, 128:39-43.
21. Virrey JJ, Guan S, Li W, Schonthal AH, Chen TC, Hofman FM. Increased survivin expression confers chemoresistance to tumor-associated endothelial cells. Am J Pathol 2008, 173:575-585. 10.2353/ajpath.2008.071079, 2475793, 18599610.
22. Zhang M, Mukherjee N, Bermudez RS, Latham DE, Delaney MA, Zietman AL, Shipley WU, Chakravarti A. Adenovirus-mediated inhibition of survivin expression sensitizes human prostate cancer cells to paclitaxel in vitro and in vivo. Prostate 2005, 64:293-302. 10.1002/pros.20263, 15754318.
23. Zhang M, Latham DE, Delaney MA, Chakravarti A. Survivin mediates resistance to antiandrogen therapy in prostate cancer. Oncogene 2005, 24:2474-2482. 10.1038/sj.onc.1208490, 15735703.
24. Yang H, Fu JH, Hu Y, Huang WZ, Zheng B, Wang G, Zhang X, Wen J. Influence of SiRNA Targeting Survivin on Chemosensitivity of H460/cDDP Lung Cancer Cells. J Int Med Res 2008, 36:734-747.
25. Duffield-Lillico AJ, Reid ME, Turnbull BW, Combs GF, Slate EH, Fischbach LA, Marshall JR, Clark LC. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: A summary report of the nuritional prevention of cancer trial. Cancer Epidemiol Biomarkers Prev 2002, 11:630-639.
26. Li H, Stampfer MJ, Giovannucci EL, Morris JS, Willett WC, Gaziano JM, Ma J. A prospective study of plasma selenium levels and prostate cancer risk. J Natl Cancer Inst 2004, 96:696-703. 10.1093/jnci/djh125, 15126606.
27. Ip C, Thompson HJ, Zhu Z, Ganther HE. In vitro and in vivo studies of methylseleninic acid: evidence that a monomethylated selenium metabolite is critical for cancer chemoprevention. Cancer Res 2000, 60:2882-2886.
28. Ip C, Birringer M, Block E, Kotrebai M, Tyson JF, Uden PC, Lisk DJ. Chemical speciation influences comparative activity of selenium-enriched garlic and yeast in mammary cancer prevention. J Agric Food Chem 2000, 48:2062-2070. 10.1021/jf000051f, 10888499.
29. Li GX, Lee HJ, Wang Z, Hu H, Liao JD, Watts JC, Combs GF, Lu J. Superior in vivo inhibitory efficacy of methylseleninic acid against human prostate cancer over selenomethionine or selenite. Carcinogenesis 2008, 29:1005-1012. 10.1093/carcin/bgn007, 18310093.
30. Medina D, Thompson H, Ganther H, Ip C. Se-methylselenocysteine: a new compound for chemoprevention of breast cancer. Nutr Cancer 2001, 40:12-17. 10.1207/S15327914NC401_5, 11799917.
31. Dong Y, Lee SO, Zhang H, Marshall J, Gao AC, Ip C. Prostate specific antigen expression is down-regulated by selenium through disruption of androgen receptor signaling. Cancer Res 2004, 64:19-22. 10.1158/0008-5472.CAN-03-2789, 14729601.
32. Dong Y, Zhang H, Gao AC, Marshall JR, Ip C. Androgen receptor signaling intensity is a key factor in determining the sensitivity of prostate cancer cells to selenium inhibition of growth and cancer-specific biomarkers. Mol Cancer Ther 2005, 4:1047-1055. 10.1158/1535-7163.MCT-05-0124, 16020662.
33. Azrak RG, Frank CL, Ling X, Slocum HK, Li F, Foster BA, Rustum YM. The mechanism of methylselenocysteine and docetaxel synergistic activity in prostate cancer cells. Mol Cancer Ther 2006, 5:2540-2548. 10.1158/1535-7163.MCT-05-0546, 2826137, 17041098.
34. Azrak RG, Frank CL, Ghadersohi A, Rustum YM. Silencing survivin results in synergy between methylseleninic acid and paclitaxel against skov3 ovarian cancer cells. Cancer Biol Ther 2008, 7:1901-1908.